Authors
Rishabh Ahuja, Vaibhav Shivhare, Dipesh Barde, Surendra Kumar Ahirwar, Ankit Mishra, Avinash Singh Mandloi, Anindya Basu, Anita Dutt Konar
Published in
Chembiochem : a European journal of chemical biology. Volume 27. Issue 15. Pages e70466. Aug 14, 2026.
Abstract
To overcome the limitations of microbial infections in modern medicine, we developed compound I incorporating the amphiphile 12-hydroxy lauric acid (12-HDA) at the N-terminus linked to a heterochiral diphenylalanine motif (D- and L-Phe) at the C-terminus guided by the principle of chiral orchestration (R. Ahuja, M. Singh, and A. Dutt Konar, ACS Appl. Biomater. 2025, 8, 1108). Although preliminary minimum inhibitory concentration (MIC) data indicated encouraging antimicrobial activity against the Gram-positive pathogens Staphylococcus aureus and Bacillus subtilis, these results alone were insufficient to consider the molecule a viable therapeutic lead. Consequently, comprehensive in vitro evaluation revealed a pronounced, organism-dependent response: Compound I reduced B. subtilis colony formation by 98%, compared to only 22% for S. aureus. Flow cytometric Live/Dead analyses corroborated these findings, showing increased cellular granularity, enhanced PI uptake, and 59.6% non-viable B. subtilis cells, whereas S. aureus exhibited limited susceptibility. Motivated by this selectivity, we evaluated Compound I in a B. subtilis-infected excisional wound model, where treated animals achieved complete wound closure, robust hair regrowth, and scar-free healing within 14 days, comparable to that of the standard drug. Overall, these findings establish compound I as a strong therapeutic candidate for future wound dressing.
PMID:
42555837
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0